Sabin Vaccine Institute 2012 Annual Report
20 Years of Advancing Smart Solutions for Vaccine-Preventable and Neglected Tropical Diseases
20 Years of Advancing Smart Solutions for Vaccine-Preventable and Neglected Tropical Diseases Annual Report 2012 For 20 years, the Sabin Vaccine Institute has invested in advancing smart solutions to vaccinepreventable and neglected tropical diseases. Extremely low-cost interventions strengthen communities and boost economies. Through research and advocacy, we advance public health initiatives that are not only cost-effective, but sustainable for the long term. We invite you to join us in our continuing efforts over the next 20 years. Table of Contents 3 4 8 12 16 20 26 28 29 30 32 Letter from the Chairman, CEO and President A History of Smart Investments in Health Fostering a Decade of Vaccines Unprecedented Research and Development Creating a Movement Snapshot of Key Moments Expanding in Europe Board of Trustees and Senior Leadership Awards and Recognition Financial Report Thank You 1 2 Letter from the Chairman, CEO and President We are pleased to present the Sabin Vaccine Institute (Sabin) 2012 annual report. The past year marked the 20th year of Sabin’s operations, which have included groundbreaking programs in vaccine development and advocacy projects helping the world’s poor gain access to much-needed vaccines and medicine. Our performance over the past two decades is a testament to the spirit of innovation, partnership and strategic leadership that Sabin has brought to the global health community. Through this work, we are uniquely positioned to deliver on the promise of a healthier future for billions of people. During the past year, we advanced the effort to achieve universal access to vaccines. Our Vaccine Advocacy and Education program, led by Dr. Ciro de Quadros, launched the International Association of Immunization Managers, the first global professional association for immunization program managers. We became a core partner in the new ProVac International Working Group, which is expanding an innovative model to help countries decide when to introduce new vaccines. Our Sustainable Immunization Financing program grew to 18 pilot countries, scaling up our efforts to strengthen national sources of funding for immunization programs. In addition, we spearheaded advocacy initiatives to reduce the burden of typhoid and paratyphoid fevers, dengue fever, meningococcal disease, pneumococcal disease, rotavirus, and rubella and congenital rubella syndrome, among others. Under the leadership of Dr. Peter Hotez, the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) is at the forefront of developing and testing new vaccines to prevent neglected tropical diseases (NTDs). In 2012, our human hookworm vaccine candidate, Na-GST-1, entered clinical trials in the United States; concurrently, in an ongoing clinical trial in Brazil, no safety issues were observed when healthy adults who had not been exposed to hookworm received the vaccine. We began a toxicology study for our schistosomiasis vaccine candidate, in preparation for filing an investigational new drug application in 2013. Additionally, we expanded our portfolio with new vaccine projects focused on Chagas disease, leishmaniasis and severe acute respiratory syndrome (SARS). The Global Network for Neglected Tropical Diseases, headed by Dr. Neeraj Mistry, also had a pivotal year as we worked with our international partners to expand and strengthen NTD control programs. In 2012, we mobilized funding to deliver life-changing NTD treatments to more than 90 million people. With support from philanthropist Dr. Gary Michelson, we announced the appointment of four new NTD Special Envoys who raise the visibility of the effects of debilitating NTDs among heads of state and senior government officials. Furthermore, we launched an exciting new advocacy campaign called END7, which works in partnership with celebrities and entertainment and media companies to promote the NTD cause to millions of people. Our work over the past 20 years has reinforced our conviction that good health is essential to enabling communities to break free from poverty. As we face the challenges and opportunities of the next decade, we look forward to continuing our collaboration with partners and supporters from around the world. We thank you for your commitment to Sabin Vaccine Institute’s vision of healthy, prosperous communities everywhere. Morton P. Hyman Chairman Michael W. Marine, Ambassador (Ret.) CEO Peter J. Hotez, M.D., Ph.D. President 3 A History of Smart Investments in Health TO IMPROVE THE LIVES OF BILLIONS 20 Years at Work Translating Our Mission into Action At Sabin, we focus on reducing needless human suffering from vaccinepreventable and neglected tropical diseases by developing new vaccines, advocating for increased use of existing vaccines and promoting expanded access to affordable medical treatments. Since the start of our Human Hookworm Vaccine Initiative in 2000, Sabin has become a leader in the world of non-profit vaccine product development. Today, the Sabin Vaccine Institute Product Development Partnership unites a group of experienced research institutions, national and international manufacturers and other partners to advance a portfolio of five vaccine projects, with more to come in 2013. In 2012, our staff published more than 25 peer-reviewed and scientific journal articles in outlets that include the Lancet, Vaccine, British Medical Journal, Journal of Allergy and Clinical Immunology, PLOS Neglected Tropical Diseases and many others. We specialize in advocacy. We engage global leaders and public institutions by convening coalitions, hosting training sessions and conferences, and conducting new research to ensure that decision-makers have the bestavailable information on vaccine-preventable diseases. 5 20 Years at Work 50 ¢ We have successfully increased the visibility of seven NTDs that infect more than 1 billion people around the world. One of our initiatives – the Global Network for Neglected Tropical Diseases – has played an indispensible role in leading global advocacy for the control and elimination of the most common of these diseases, that have plagued the world's poor since biblical times. The fight against these diseases – which can be treated for approximately 50 cents per person per year – is gaining increased global political and public support each year. A Brighter Future We are confident in our ability to achieve ambitious health goals. By the year 2020, we anticipate contributing to the next major milestones in public health, including controlling or eliminating up to 10 NTDs as public health threats; developing new vaccines that will free more than 1 billion people from the threat of NTDs and other infectious diseases; and exceeding Millennium Development Goal 4 by reducing child deaths by two-thirds compared to 1990 through expanding access to new and underutilized vaccines. 6 20 Years at Work Major Funding Commitments Supporting Sabin Programs Over the past five years, we have secured grant commitments totaling more than US $120 million. Some of our most significant grants are listed below. VACCINE ADVOCACY AND EDUCATION THE SABIN PDP THE GLOBAL NETWORK FOR NEGLECTED TROPICAL DISEASES received US $9 million+ in grants for 18 individual programs and events to advocate for immunization in 2012. Major grants over the past five years include: US $9.2 MILLION received US $6 million+ in grants in 2012 while continuing to seek additional funding for ongoing research and development activities. Major grants over the past five years include: US $12.1 MILLION received US $40 million in grants since 2008 to conduct advocacy and resource mobilization efforts that leveraged US $114 million in resources for NTD treatment programs. Major grants over the past five years include: US $37.6 MILLION over five years from the Bill & Melinda Gates Foundation to support the Sustainable Immunization Financing program US $4.9 MILLION over four years from the Bill & Melinda Gates Foundation to support our human hookworm vaccine â‚Ź 5.9 MILLION over five years from the Bill & Melinda Gates Foundation to mobilize resources and conduct strategic advocacy work for NTD treatment programs US $1 MILLION over five years from the Bill & Melinda Gates Foundation to support the International Association of Immunization Managers US $3.7 MILLION over four years from the Dutch Ministry of Foreign Affairs to support the development of the human hookworm vaccine US $1.3 MILLION over four years from the Hoffman Family Foundation in support of NTD treatment programs over three years from the Bill & Melinda Gates Foundation to support the Coalition against Typhoid Secretariat US $2 MILLION in philanthropic funding to support our schistosomiasis vaccine from Mort and Chris Hyman, the Blavatnik Family Foundation and Dr. Gary Michelson over three years from sanofi pasteur to support advocacy related to the pertussis vaccine 7 Fostering a Decade of Vaccines TO EXTEND THE BENEFITS OF IMMUNIZATION TO ALL Vaccine Advocacy and Education “ We must prioritize the critical health issues of the young, the old and everyone in between in the public health agenda, so that no one suffers from vaccine-preventable diseases.” Dr. Ciro de Quadros Vaccines are some of the most valuable public health tools available today. However, challenges still remain in our work to ensure that people – no matter who they are or where they are born – have full access to all lifesaving vaccines. In the last year, Sabin played a critical role in the development of a new roadmap for making vaccines accessible to everyone by 2020. Sabin Executive Vice President Dr. Ciro de Quadros served as a co-chair of the Steering Committee for the Decade of Vaccines Collaboration, which led the development of the Global Vaccine Action Plan that was unanimously endorsed by the World Health Assembly in May 2012. Enhancing Decision-Making and Strengthening Country Ownership We expanded our vaccine advocacy operations with the start of two new initiatives focused on educating stakeholders and decision-makers. We launched the International Association of Immunization Managers (IAIM), the first global professional association for immunization program managers – those who manage the day-to-day operations of national immunization programs. hrough our leadership in the new T ProVac International Working Group – first developed and tested by the Pan American Health Organization (PAHO) – Sabin is helping countries to conduct economic analyses prior to deciding to introduce new vaccines. Sabin’s long-standing Sustainable Immunization Financing (SIF) program demonstrated measurable progress in increasing country-level commitment to immunization, as the number of countries involved in this pilot effort grew to 18, and the SIF team facilitated more than 90 advocacy events, including national briefings, meetings and peer exchanges throughout the year. 9 Vaccine Advocacy and Education Lending Our Voices to Disease Prevention Efforts Preventable diseases like meningitis, typhoid and paratyphoid fevers, rotavirus, dengue fever, pneumonia, rubella and congenital rubella syndrome, pertussis and human papilloma virus (HPV) take the lives of nearly 2 million people every year. Sabin addresses the clear need for increased global action to prevent these diseases through targeted advocacy, education and training. PATHWAY FOR NEXT GENERATION TYPHOID VACCINES Serving as the Secretariat of the Coalition against Typhoid (CaT), Sabin began work with the World Health Organization (WHO) to define the regulatory pathway for next generation typhoid vaccines and convened experts in mathematical modeling to review state-of-the-art typhoid transmission models. ERADICATE MEASLES AND RUBELLA IN EVERY REGION ADDRESS DENGUE In 2012, Sabin partnered with the International Pediatric Association in a joint effort to eradicate measles and rubella in every region by 2020. Through our work in the Dengue Vaccine Initiative, we increased public awareness and political will to address this mosquito-borne disease, which threatens 40 percent of the worldâ€™s population. Additionally, in 2012 Sabin organized conferences, trainings and educational sessions, attracting hundreds of high-level decision-makers representing government, academia, civil society and the media. Together with PAHO, we hosted the First Regional Meningococcal Symposium in Latin America, which shared preliminary data from a Sabin-led study on the burden and costs of meningococcal disease in the region, estimated at US $50-60 million annually. We also convened more than 300 stakeholders at the 10th International Rotavirus Symposium in Thailand. 10 Vaccine Advocacy and Education 24-26 million estimated future deaths could be averted by meeting the immunization goals of the Global Vaccine Action Plan $9 million+ in grants received for 18 individual programs and events to advocate for immunization in 2012 100+ stakeholder meetings, conferences and trainings convened in 2012 18 pilot countries included in the expanded Sustainable Immunization Financing program Launched the first global professional association for immunization program managers 11 Development TO PREVENT DISEASE, REDUCE ILLNESS AND BOLSTER ECONOMIES Unprecedented Research and The Sabin Vaccine Institute Product Development Partnership “ We are filling a gap to produce vaccines for the world’s poorest people, where no traditional commercial market exists.” Dr. Peter Hotez In 2012, the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) accelerated efforts to develop and test new vaccines. We expect significant progress over the next five years as we prepare to transition several vaccine candidates into clinical trials and continue ongoing trials for our human hookworm vaccine. HOOKWORM VACCINE CLINICAL TRIALS ADVANCE The ongoing Phase 1 clinical trial of our hookworm vaccine candidate Na-GST-1 moved to Part II after an independent Safety Monitoring Committee determined that the vaccine candidate resulted in no safety issues for healthy adults who had never been exposed to hookworm. Subsequently, hookworm-exposed adults started receiving the vaccine candidate. We commenced a second Phase 1 clinical trial for healthy adults of Na-GST-1 at Children’s National Medical Center in Washington, D.C. In addition, we submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for our second hookworm vaccine candidate, Na-APR-1, a necessary step prior to conducting clinical testing, which is expected to begin in 2013. EW CUTANEOUS LEISHMANIASIS N VACCINE STRATEGIES Since 2011, the Sabin PDP has been working to identify new strategies for the development of a vaccine to prevent cutaneous leishmaniasis, the most common form of leishmaniasis, which is transmitted by the bite of a sand fly and infects as many as 1.2 million people each year. 13 The Sabin Vaccine Institute Product Development Partnership BUILDING MOMENTUM I N SCHISTOSOMIASIS VACCINE DEVELOPMENT and is linked to a multifold increase in acquiring HIV/AIDS. Our intestinal schistosomiasis vaccine candidate, Sm-TSP-2, began a Good Laboratory Practices toxicology study in 2012 – an important step that will determine preclinical safety of the vaccine candidate and enable submission of an IND application to the U.S. Food and Drug Administration in 2013, to be followed by the start of Phase 1 clinical testing. Schistosomiasis is one of the world's most damaging and deadly parasitic infections. The intestinal form infects more than 80 million people, causing anemia and hemorrhaging. Female genital schistosomiasis is the most common gynecologic condition in Africa, affecting as many as 120 million girls and young women, NEW THERAPEUTIC A VACCINE FOR CHAGAS DISEASE disease vaccine could prevent more than 10,000 deaths from the disease each year. With support from the Carlos Slim Institute for Health, the Southwest Electronic Energy Medical Research Institute, Texas Children’s Hospital and other academic and industrial partners, the Sabin PDP is in the early preclinical stages of developing a new therapeutic vaccine targeting Chagas disease. Chagas disease is a leading cause of heart disease, affecting approximately 10 million people, primarily in Latin America. The only drugs available to treat Chagas disease today have limitations – treatment courses are often costly and lengthy and may not always be effective. A therapeutic Chagas STRENGTHENING BIODEFENSE WITH A SARS VACCINE as the elderly and health care and laboratory personnel in the face of future outbreaks. The Sabin PDP – together with partners in industry, academia and the military – is working to develop and manufacture a SARS vaccine within the next five years. Severe acute respiratory syndrome (SARS) emerged as a global cause for concern when it produced more than 8,000 infections and approximately 800 deaths in China from 2002-2003. A SARS vaccine could protect vulnerable populations such 14 The Sabin Vaccine Institute Product Development Partnership $6 million+ in grants received in 2012. We continue to seek additional funding for ongoing research and development activities Hookworm vaccine candidate progressing in two Phase 1 clinical trials Schistosomiasis vaccine candidate prepared for IND submission Vaccines in development New vaccines will tackle diseases to address 5 diseases that infect 1 billion+ people 15 Movement Creating a TO CONTROL AND ELIMINATE KEY NEGLECTED TROPICAL DISEASES THIS DECADE Global Network for Neglected Tropical Diseases “ Drug donations from pharmaceutical companies are just the beginning of a comprehensive collaboration between the private sector, NGOs and country governments that will help us to meet our 2020 control and elimination targets for neglected tropical diseases.” Dr. Neeraj Mistry Since 2006, the Global Network for Neglected Tropical Diseases (Global Network) has led the charge in raising the awareness, political will and resources necessary to eliminate and control the seven most common neglected tropical diseases (NTDs): hookworm, whipworm, roundworm, lymphatic filariais (elephantiasis), schistosomiasis (bilharzia), onchocerciasis (river blindness) and trachoma. In early 2012, under the leadership of the Bill & Melinda Gates Foundation, WHO, World Bank and others, the global community came together in an unprecedented way to sign the London Declaration on NTDs, a commitment to control and eliminate 10 NTDs by 2020. As a signatory of the London Declaration, the Global Network is working to meet the ambitious but achievable challenges set for this decade. Catalyzing New Funding NTDs on the Global Agenda We cultivated strong support for NTD programs in the United States and abroad. We briefed more than 250 members of the U.S. Congress about NTDs through policy briefings, visits and targeted outreach throughout the year. U.S. government funding for NTD programs increased from US $15 million in fiscal year (FY) 2006 – the first year of funding – to US $89 million in FY 2012. The United Kingdom announced a five-fold increase to its commitment to NTD programs in early 2012 to £245 million over four years – evidence that NTD treatment is a wellrecognized, vital and cost-effective way to improve lives around the world. 17 50 ¢ Fifty cents can be incredibly powerful. It’s the annual cost to treat and protect an individual from the seven most common NTDs. In 2012, we mobilized enough new funding to treat more than 90 million people against NTDs through programs in endemic countries, and, since 2008, we mobilized sufficient funding to treat more than 300 million people. Global Network for Neglected Tropical Diseases In addition, we significantly expanded our efforts to engage governments beyond the United States and United Kingdom in support of costeffective NTD programs through 15 international high-level advocacy trips to meet with senior government officials in parliament, bilateral aid agencies, presidential offices, and ministries of health and foreign affairs. Strengthening Regional Institutions With partners at WHO regional offices, regional development banks, non-governmental organizations and country governments, we helped to create and advance sustainable NTD policies and programs in the three regions where the burden is the highest: Africa; Asia and the Pacific; and Latin America and the Caribbean. By the end of 2012, nearly 60 countries had national integrated plans of action for NTD control. In Africa, three countries – Burundi, Cameroon and Mozambique – launched their national NTD plans in 2012. In Latin America and the Caribbean, Honduras and Brazil became the first countries to launch their national integrated NTD plans, while 11 other countries in the region made progress in developing draft plans. Meanwhile, in Asia, the Western Pacific and South-East Asia regions both launched NTD Regional Strategic Action Plans. Winning over the Public We launched the END7 campaign in January 2012 to engage the general public in the work to control and eliminate NTDs. The campaign achieved important metrics of success in its first year by recruiting more than 30 actors, musicians and other influential members of the entertainment industry to participate in a Twitter “Day of Action” that reached more than 50 million people with important information on NTDs. 18 Global Network for Neglected Tropical Diseases 60 countries have national, integrated plans to address NTDs $40 million in grants received since 2008 to conduct advocacy and resource mobilization efforts that leveraged US $114 million in resources for NTD treatment programs US and UK governments made increased commitments to NTD programs of US $89 million and ÂŁ245 million, in 2012 In its first year, the END7 campaign reached Since 2008, mobilized funding to support 50 million+ people treatment of 300 million+ people 19 Snapshot of Key Moments CATALYTIC EVENTS FROM 2012 20 2012 at a Glance THE CALL TO FIGHT NTDS FIRST REGIONAL MENINGOCOCCAL SYMPOSIUM PROGRESS TOWARD RUBELLA ELIMINATION AND CRS PREVENTION IN EUROPE Rome, Italy Sabin, together with the March of Dimes Foundation, the World Health Organization Regional Office for Europe, the International Pediatric Association and its regional affiliate, the European Pediatric Association and the U.S. Centers for Disease Control and Prevention (CDC), convened more than 150 people from 47 countries to review the latest developments in the fight against rubella and congenital rubella syndrome in Europe. Buenos Aires, Argentina Sabin and the Pan American Health Organization (PAHO) convened a symposium to reveal preliminary results from the first-ever study to estimate the burden and costs of meningococcal disease in Latin America. Preliminary data suggested at least 10,000 cases of meningococcal disease occur each year, costing the region US $50-60 million in hospitalizations, opportunity costs and long-term disability. Washington, D.C., USA The Center for Strategic and International Studies and the Global Network called together key leaders in Washington, D.C. to highlight emerging African leadership and philanthropy in the fight against NTDs, particularly the leadership of Nigerian General T.Y. Danjuma, the London Declaration and multisectoral partnerships, such as the World Bankâ€™s African Programme for Onchocerciaisis Control. NEW NTD SPECIAL ENVOYS ANNOUNCED Washington, D.C., USA His Excellency John A. Kufuor (President of the Republic of Ghana, 2001-2009), His Excellency, President Alvaro ArzĂş Irigoyen of Guatemala (1996-2000), His Excellency, President Ricardo Lagos Escobar of Chile (2000-2006) and former PAHO Director Dr. Mirta Roses Periago joined Sabin and the Global Network as NTD Special Envoys. 21 2012 at a Glance GLOBAL VACCINE ACTION PLAN ENDORSED BY WORLD HEALTH ASSEMBLY THE 15TH INTERNATIONAL CONGRESS ON INFECTIOUS DISEASES Geneva, Switzerland In May 2012, the 65th World Health Assembly endorsed the landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to new and existing vaccines. The GVAP was coordinated by the Decade of Vaccines (DoV) Collaboration, a group of international vaccine experts representing leading global health organizations. Sabin Executive Vice President Dr. Ciro de Quadros served as co-chair of the DoV Steering Committee. Bangkok, Thailand The Sabin-led Coalition against Typhoid (CaT) Secretariat convened breakout sessions during the 15th International Congress on Infectious Diseases to discuss the high burden of endemic typhoid in South and Southeast Asia and the Pacific Islands. NEW CLINICAL TRIAL OF HUMAN HOOKWORM VACCINE BEGINS GLOBAL HEALTH RESEARCH AND DEVELOPMENT AND THE HIDDEN BURDEN OF NEGLECTED TROPICAL DISEASES IN TEXAS Washington, D.C., USA The Sabin PDP, in partnership with The George Washington University and the Children’s National Medical Center, began vaccinating participants in a Phase 1 clinical trial of Na-GST-1, one of our human hookworm vaccine candidates. Houston, Texas, USA Sabin partnered with Research!America, Baylor College of Medicine’s National School of Tropical Medicine, Texas Children’s Hospital and the American Society of Tropical Medicine and Hygiene to convene a day-long event with more than 150 attendees that revealed the hidden burden of neglected tropical diseases in Texas. 22 2012 at a Glance ALLIED TO FIGHT AGAINST NTDS: CONTRIBUTIONS OF THE PRIVATE SECTOR Berlin, Germany Together with vfa, an association of leading research-based pharmaceutical companies in Germany, the Global Network led expert discussions on strategies for improved collaboration and increased private sector involvement in NTD treatment and control programs. Two separate events brought together more than 100 individuals representing industry, civil society, media and academia, the ambassadors of 10 countries, and German government officials and members of Parliament. THE 10TH INTERNATIONAL ROTAVIRUS SYMPOSIUM SABIN PARTNERS WITH EISAI FOR VACCINE ANTIGENS Sabin and Eisai Co., Ltd. announced a new collaboration to advance vaccine development efforts. Eisai provided adjuvant material to enable the Sabin PDP to expand ongoing research and development for its leishmaniasis and Chagas disease vaccine candidates. Bangkok, Thailand Sabin, PATH, the Bill & Melinda Gates Foundation and the CDC brought together more than 300 stakeholders from 47 countries for an update on new data and relevant research to inform public health agendas related to prevention of rotavirus gastroenteritis, the most common cause of diarrheal hospitalizations and deaths among children worldwide. SABIN AND THE INTERNATIONAL VACCINE INSTITUTE FORM STRATEGIC ALLIANCE Seoul, Korea The International Vaccine Institute and Sabin signed a memorandum of understanding to form a strategic alliance around research, development and advocacy in support of vaccines and public health efforts impacting the worldâ€™s poorest populations. THE 14TH ASIA PACIFIC CONGRESS OF PEDIATRICS CELEBRATING AN UNTOLD STORY OF SUCCESS SABIN AND ASEAN FOUNDATION JOIN TOGETHER AGAINST NTDS Jakarta, Indonesia Sabin and the Global Network began to work with ASEAN Foundation, an inter-governmental non-profit organization established by the leaders of the Association of Southeast Asian Nations, to encourage greater dialogue and action on NTD control in the Asia and Pacific region. Washington, D.C., USA The Global Network jointly sponsored an event on Capitol Hill with the U.S. Agency for International Development and 40 other non-governmental organizations, academic institutions, pharmaceutical companies, and global health and civil society groups to celebrate the success of global partnerships that combat NTDs and announce the addition of NTDs to the Senate Working Group on Malaria. Kuching, Malaysia The CaT Secretariat called together leading pediatricians from across Asia to encourage discussion of the hyper-endemic burden of typhoid in the region, including antibioticresistant typhoid, and offer solutions such as vaccine introductions to combat this growing problem. 23 2012 at a Glance SCHISTOSOMIASIS VACCINE CANDIDATE BEGINS TOXICOLOGY STUDY Chicago, Illinois, USA A Good Laboratory Practices toxicology study commenced to determine the safety, tolerability and potential toxicity of our intestinal schistosomiasis vaccine candidate, Sm-TSP-2, in laboratory animals. PLOS NTDS OPEN ACCESS JOURNAL CELEBRATES FIFTH ANNIVERSARY SECOND VACCINOLOGY COURSE FOR LATIN AMERICA FIFTH GAVI PARTNER’S FORUM San Francisco, California, USA The open-access journal, PLOS NTDs, celebrated its fifth anniversary by releasing a collection called “The Geopolitics of NTDs.” Sabin President Dr. Peter Hotez, who helped to spearhead the publication, is currently the co-Editor-in-Chief. Lima, Peru Together with the Universidad Peruana Cayetano Heredia, Sabin assembled 40 country delegates and 25 expert speakers in vaccinology to discuss current vaccines and immunization recommendations, funding mechanisms and effective use of communications to help reduce vaccine-preventable diseases. VACCINE INFORMATION SESSION São Paulo, Brazil In partnership with the Brazilian Immunization Society, Sabin arranged a three-day information session for 22 global health journalists from nine countries in the Latin America and Caribbean region to provide the most recent information on vaccines and the process of delivery as background for public health stories. COUNTRY IMMUNIZATION LEGISLATIVE WORKSHOP Dar es Salaam, Tanzania Sabin’s SIF program worked with the GAVI Alliance (Global Alliance for Vaccines and Immunisation) to produce a series of sessions attended by members of parliament representing 13 African, Asian and European countries. Nine members of parliament spoke of their advocacy work in SIF countries. Sabin Executive Vice President Dr. Ciro de Quadros, a member of the forum’s organizing committee, presided over two sessions. Kinshasa, Democratic Republic of Congo Sabin’s Sustainable Immunization Financing (SIF) program sponsored a workshop on legislative and financial strategies for immunization. The workshop drew delegates from ministries of health, ministries of finance and parliaments of six Francophone countries. Workshop participants conducted peer reviews of draft laws and shared strategies for strengthening routine immunization program financing. 24 Expanding in Europe TO REALIZE BIGGER GOALS AND GREATER RESULTS Sabin Foundation Europe Sabin Foundation Europe (SFE), a key partner organization of the Sabin Vaccine Institute working in the United Kingdom and across Europe, significantly scaled up efforts to raise awareness and spur action to reduce the effects of vaccine-preventable and neglected tropical diseases (NTDs). High-Level Advocacy Efforts in the United Kingdom RT. HON. BARONESS HELENE HAYMAN GBE, a member of the Sabin Vaccine Institute Board of Trustees, twice fueled interest in NTD elimination efforts in the House of Lords. Following the launch of the London Declaration on NTDs, Baroness Hayman led a parliamentary debate titled “Health: Neglected Tropical Diseases,” where she applauded the UK Department for International Development’s new funding commitments toward NTD programs. In July, she pressed for further attention to NTDs in the context of broader health programs focused on HIV/AIDS, malaria and tuberculosis. URGING POLICYMAKERS TO TAKE ACTION ON NTDS In June, UK Member of Parliament and Trustee of Sabin Foundation Europe Jeremy Lefroy urged his colleagues in the House of Commons and Prime Minister David Cameron to take action on NTDs and to continue to engage partner governments and organizations as well as the British public in their efforts. He was joined in his efforts by Mr. Stephen O’Brien, then the UK Parliamentary Under-Secretary of State for International Development (2010 – 2012), and a long-time champion for malaria and NTD programs. John Cummins Joins Board of Trustees In January 2013, John Cummins, Group Treasurer of the Royal Bank of Scotland, joined Sabin Foundation Europe’s Board of Trustees. The Sabin Foundation Europe Board of Trustees Morton P. Hyman Chairman John Cummins Group Treasurer, Royal Bank of Scotland Jeremy Lefroy Member of Parliament, Stafford Constituency, House of Commons, Chairman, All-Party Parliamentary Group on Malaria and NTDs William D. Morrison Chairman and Member of the Board, Trinity Group 27 The Sabin Vaccine Institute 2012 Board of Trustees and Senior Leadership Board of Trustees Morton P. Hyman Chairman Founder and CEO of MPH Enterprises, LLC Peter L. Thoren Executive Vice President, Access Industries, Inc. PROGRAM LEADERSHIP Maria Elena Bottazzi, Ph.D. Director, Product Development, Sabin PDP Baylor College of Medicine Texas Children’s Hospital Michael E. Whitham Secretary and Treasurer Founding partner, Whitham, Curtis, Christofferson & Cook Allan L. Goldstein, Ph.D. Professor and Emeritus Chairman Department of Biochemistry & Molecular Biology, The George Washington University School of Medicine Michelle K. Brooks Director, Policy, Global Network for Neglected Tropical Diseases Heloisa Sabin Honorary Trustee Peter Carrasco Senior Leadership EXECUTIVE LEADERSHIP Director, International Association of Immunization Managers (IAIM) Secretariat Rt. Hon. Baroness Helene Hayman, GBE Immediate Past Lord Speaker of the House of Lords, United Kingdom Parliament Michael W. Marine, Ambassador (Ret.) Chief Executive Officer Ana Flavia Carvalho, M.B.A., M.P.H. Director, Special Projects, Vaccine Advocacy and Education Peter J. Hotez, M.D., Ph.D. President, Director, Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development Axel Hoos, M.D., Ph.D. Vice President, Oncology R&D, GlaxoSmithKline Pharmaceuticals David Diemert, M.D., FRCP(C) Director, Clinical Trials, Sabin PDP The George Washington University Kevin L. Reilly Former Chairman of the Board, VaxGen, Inc. Richard J. Hatzfeld Director, Communications Ciro de Quadros, M.D., M.P.H. Executive Vice President, Director, Vaccine Advocacy and Education Tara Hayward Director, Resource Development Gary Rosenthal Partner in the Sterling Group, L.P. Immediate Past Chairman of the Board of Trustees, Texas Children’s Hospital Marva Loblack, M.S., M.B.A. Director, Regulatory Affairs and Quality Assurance, Vaccine Development Neeraj Mistry, M.D., M.P.H. Managing Director, Global Network for Neglected Tropical Diseases Philip K. Russell, M.D. Past Chairman Major General, U.S. Army Medical Corps (Ret.) Mike McQuestion, Ph.D., M.P.H. Director, Sustainable Immunization Financing Brian Davis, C.P.A. Chief Operating Officer Larry Ellingsworth, Ph.D. Vice President, Deputy Director, Sabin PDP Christopher B. Nelson, Ph.D., M.P.H. Director, Coalition against Typhoid Secretariat Marc Shapiro Non-Executive Chairman, Chase Bank of Texas Immediate Past Chairman of the Board of Trustees, Baylor College of Medicine 28 Marcia de Souza Lima, M.D., M.I.P.P. Director, Programs and Operations, Global Network for Neglected Tropical Diseases The Sabin Vaccine Institute 2012 Awards and Recognition Awards and Appointments for Sabin Leadership Sabin Executive Vice President Dr. Ciro de Quadros was awarded the prestigious BBVA Frontiers in Knowledge Award in the Development Cooperation category for leading the efforts to eliminate polio and measles from the western hemisphere and being one of the most important scientists in the eradication of smallpox around the world. Dr. de Quadros adds this latest achievement to other awards and recognition he has received over the past three years from prestigious organizations including Case Western University, PAHO, the Royal National Academy of Medicine in Spain, the Brazilian Ministry of Health, and Rotary International, among many others. Sabin President Dr. Peter Hotez was appointed as the Baker Institute Fellow in Disease and Poverty at the James A. Baker III Institute for Public Policy at Rice University. In addition, he received the Ralph D. Feigin, M.D. Award for Excellence from the Immunization Partnership, and became an elected member of the Association of American Physicians and a member of the Editorial Board of the Journal of Pediatric Infectious Diseases Society. The United Nations Economic and Social Council (ECOSOC) granted special consultative status to Sabin in 2012, a new opportunity to actively engage with ECOSOC and its subsidiary bodies, as well as with the United Nations Secretariat programs, funds and agencies. Dr. Hotez adds these to his recent appointments, fellowships and memberships over the past three years from Baylor College of Medicine, Texas Children’s Hospital, The Academy of Medicine, Engineering and Science of Texas (TAMEST), NIH Council of Councils, American Society of Tropical Medicine and Hygiene and the National Library of Medicine, among many others. Sabin Vaccine Institute Recognition and Appointments In 2012, Sabin received Charity Navigator’s highest 4-Star rating for the fifth consecutive year, a ranking that reflects our commitment to transparency, accountability and careful stewardship of funding. Sabin was also appointed as the 51st member of Texas Medical Center, the world’s largest medical center. All member institutions of the Texas Medical Center are non-profit organizations devoted to research, education, patient care and the prevention of disease and injury. Dr. F. Marc LaForce Receives 2012 Gold Medal Award In May 2012, Sabin presented the annual Albert B. Sabin Gold Medal Award to Dr. F. Marc LaForce for his integral role in developing a new meningitis vaccine, MenAfriVac®, which has the potential to prevent 1 million cases of disease and save 150,000 lives and up to US $300 million in medical costs over the next decade. The new vaccine was developed at a cost of less than US $0.50 per dose, and to date, more than 100 million people in 10 countries have received MenAfriVac®. Not a single case of group A meningococcal meningitis has been identified in vaccinated individuals. 29 The Sabin Vaccine Institute 2012 â€“ Financial Report Condensed Statement of Activities December 31, 2012 and 2011 REVENUE AND SUPPORT 2012 2011 Grants, contributions and other support received Sabin's Board of Trustees and executive leadership are fully committed to responsible and effective stewardship of donor funding. For the fifth consecutive year, Sabin received Charity Navigator's highest rating for consistently executing our mission in a fiscally responsible way. Future portion of grants as of year-end Investment income TOTAL $25,393,978 41,598,275 31,516 67,023,769 $22,164,456 51,411,865 24,717 73,601,038 EXPENSES Program services General, administrative and fundraising TOTAL 19,401,006 2,111,781 21,512,787 22,749,027 2,217,039 24,966,066 EXCESS OF REVENUES, COMMITMENTS AND SUPPORT OVER EXPENSE $45,510,982 $48,634,972 2012 FUNCTIONAL EXPENSE ALLOCATION: Program Services 30 90% 10% General, Administrative and Fundraising The Sabin Vaccine Institute 2012 â€“ Financial Report Condensed Statement of Financial Position December 31, 2012 and 2011 ASSETS 2012 2011 Cash, equivalents and other current assets Investments Other assets TOTAL ASSETS $12,735,970 14,493,641 72,324 27,301,935 $12,893,780 12,056,655 85,095 25,035,530 The financial statements presented have been summarized from Sabin's audited financial statements. Sabin's full audit report, completed by Rogers & Co, LLP, is available at www.sabin.org. LIABILITIES AND NET ASSETS Accounts payable and accrued expenses Other liabilities TOTAL LIABILITIES 2,503,493 468,065 2,971,558 3,956,238 661,622 4,617,860 Unrestricted net assets Temporarily restricted net assets 2,138,685 22,191,692 1,982,925 18,434,745 TOTAL NET ASSETS TOTAL LIABILITIES AND NET ASSETS 24,330,377 $27,301,935 20,417,670 $25,035,530 2012 PROGRAM EXPENSE ALLOCATION: 36% Vaccine Development 36% Vaccine Advocacy and Education 28% Global Network 31 The Sabin Vaccine Insititute 2012 Thank you To Our Partners, Collaborators and Contributors from around the World A Abbott Laboratories Aeras African Programme for Onchocerciasis Control African Union Mission to the United States Aga Khan University [Pakistan] Agence de Médecine Préventive [France] American Public Health Association ASEAN Foundation Asian Development Bank Association for Immunization Managers B Baylor College of Medicine Bharat Biotech [India] Bill & Melinda Gates Foundation bioMérieux BIRMEX [Mexico] Blavatnik Family Foundation Ms. Emily Blunt Brazilian Society of Immunizations [Brazil] C Catholic Medical Mission Board CBM International Center for Research and Advanced Studies of the National Polytechnic Institute [Mexico] Center for Strategic and International Studies Center for Vaccine Development at the University of Maryland Ms. Yvonne Chaka Chaka Chiapas State Government [Mexico] Children’s National Medical Center Ms. Priyanka Chopra Communes et Villes Unies du Cameroun [Cameroon] Covington & Burling Creative Artists Agency Foundation Crucell [Switzerland] Mr. Richard Curtis D Department for International Development [United Kingdom] DiaSorin [Italy] Drugs for Neglected Diseases Initiative Dubai Cares [United Arab Emirates] E Eisai Co., Ltd. [Japan] Embassy of Nigeria [Nigeria] Embassy of South Africa [South Africa] EMI Music F Mr. Russell B. Faucett Mr. Tom Felton FEMSA Foundation [Mexico] Finlay Institute [Cuba] Fondation Mérieux [France] Fraunhofer Center for Molecular Biotechnology Frontier BioSciences, Inc. [China] Fundação Oswaldo Cruz [Brazil] Fundación Cinépolis [Mexico] Fundación Mundo Sano [Argentina] G GAVI Alliance GlaxoSmithKline Global Health Partnership Initiative Global Health Technologies Coalition Government of the Municipality of Recife [Brazil] Governments and Parliaments of Bhutan, Cambodia, Cameroon, Democratic Republic of Congo, Republic of Congo, Ethiopia, Kenya, Liberia, Madagascar, Mali, Mongolia, Nepal, Nigeria, Senegal, Sierra Leone, Sri Lanka, Uganda, Vietnam H Helen Keller International Hoffmann-La Roche Inc. Mr. Tom Hollander Hospital de Niños Dr. Ricardo Gutierrez [Argentina] Hospital de Niños Roberto del Río [Chile] Hudson Institute Mr. and Mrs. Morton and Chris Hyman I/J icddr,b [Bangladesh] IMA World Health Immune Design Corporation Institut Pasteur Instituto Balseiro [Argentina] Instituto Butantan [Brazil] Instituto Carlos Slim de la Salud [Mexico] Instituto Conmemorativo Gorgas de Estudios de la Salud [Panama] Inter-American Development Bank International Trachoma Initiative International Vaccine Institute [Republic of Korea] Ms. Aigerim Jakisheva James Cook University [Australia] L Lions Club of Nepal [Nepal] Liverpool School of Tropical Medicine [United Kingdom] London School of Hygiene and Tropical Medicine [United Kingdom] M/N March of Dimes Foundation Merck & Co., Inc. Dr. Gary K. Michelson Ministerio de Salud de la Nación [Argentina] Ministerio de Salud República de Panamá [Panama] Ministry of Foreign Affairs, Government of the Netherlands [The Netherlands] Ministry of Health of Brazil [Brazil] Ministry of Health of Thailand [Thailand] New York Blood Center Novartis Vaccines Institute for Global Health [Italy] O Oxford University Clinical Research Unit at the Hospital for Tropical Diseases [Vietnam] Oxford Vaccine Group [United Kingdom] P/Q Pan American Health Organization PATH Pfizer Inc. Planty & Associates LLC Queensland Institute of Medical Research [Australia] R Mr. Eddie Redmayne Rotary Clubs [Nepal, Cameroon] S Sanofi Pasteur SA Sanofi-Aventis U.S. LLC. Santa Casa de São Paulo [Brazil] Mrs. Alicia Zarou Scanlon Schistosomiasis Control Initiative Mr. and Mrs. Marvin and Donna Schwartz Secretaría de Salud [Mexico] 32 The Sabin Vaccine Insititute 2012 Serum Institute of India Ltd. [India] Sevenly Shantha Biotech [India] SouthWest Electronic Energy Medical Research Institute T Texas Children’s Hospital The Earth Institute at Columbia University The END Fund The Infectious Disease Research Institute The George Washington University Department of Microbiology, Immunology and Tropical Medicine The Leprosy Mission Canada [Canada] The Social Investment Consultancy The Task Force for Global Health U/V Uganda Local Governments Association [Uganda] UNICEF Universidad Autónoma de la Yucatán [Mexico] Universidad Nacional de Colombia, Departamento de Salud Publica [Colombia] Universidade Federal da Bahia, Faculdade de Medicina [Brazil] University of Kansas University of Notre Dame, Haiti Program University of Otago, New Zealand [New Zealand] University of Pittsburgh University of Texas Medical Branch U.S. Agency for International Development U.S. Centers for Disease Control and Prevention U.S. National Institutes of Health, Fogarty International Center U.S. National Institutes of Health, National Institute of Allergy and Infectious Diseases vfa [Germany] W Walter Reed Army Institute of Research Webb Family Foundation Wellcome Trust [United Kingdom] Wellcome Trust Sanger Institute [United Kingdom] World Health Organization World Health Organization Initiative for Vaccine Research (IVR) World Health Organization, Regional Office for Africa World Health Organization, Regional Office for Europe World Health Organization, Regional Office for South-East Asia World Health Organization, Western Pacific Region Wunderman [United Kingdom] Credits Photography / Cover photo: Esther Havens / pg. 2-3 Esther Havens / pg. 4 Olivier Asselin / pg. 5 Olivier Asselin / pg. 6 Jessica Stuart / pg. 7 Olivier Asselin / pg. 8 Olivier Asselin / pg. 9 Evan Wilder (top), Olivier Asselin (bottom) / pg. 10 Olivier Asselin / pg. 11 Olivier Asselin / pg. 12 National School of Tropical Medicine / pg. 13 Brett Coomer (top), Getty Images/Ingram Publishing (middle), CDC Public Health Image Library (bottom) / pg. 14 CDC Public Health Image Library (all) / pg. 15 Olivier Asselin / pg. 16 Richard Hatzfeld / pg. 17 Evan Wilder / pg. 18 Olivier Asselin / pg. 19. Esther Havens / pg. 20 Esther Havens / pg. 21 CDC Public Health Image Library (left), Gustavo Alric (middle), Esther Havens (right) / pg. 22 Svenja Knoedler (left top), Oliver Asselin (left bottom) Quo - Bangkok (middle), Anna Grove (right) / pg. 23 Deborah Hong (top right), Sayam Eiampichairit (top middle) / pg. 24 National School of Tropical Medicine (left), Olivier Asselin (right) / pg. 25 Olivier Asselin / pg. 26 Olivier Asselin / pg. 29 BBVA Foundation(left), The Immunization Partnership (middle), Evan Wilder (right) / pg. 33 Esther Havens Design / BÜRO SVENJA Carrying a Legacy Forward The Sabin Vaccine Institute was founded in 1993 in honor of Dr. Albert B. Sabin, a scientist, humanitarian and hero. His success in developing the oral polio vaccine has saved countless lives and eliminated millions of cases of illness and disability. Over the last 25 years, polio cases have been reduced by 99 percent; the economic benefit of eradicating polio is estimated to be US $40-50 billion. Sabin Vaccine Institute 2000 Pennsylvania Avenue, NW Suite 7100 Washington, D.C. 20006 Phone : +1 (202) 842-5025 Web : www.sabin.org : www.facebook.com/sabinvaccine : @sabinvaccine Printed on recycled paper using vegetable-based inks and 100% wind power.